Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study.
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies for smoking cessation, but data about their safety in pregnancy are limited. We assessed the risk of adverse perinatal outcomes and major congenital anomalies associated with the use of these therapies in pregnancy in Australia. Methods: Perinatal data for 1,017,731 deliveries (2004 to 2012) in New South Wales and Western Australia were linked to pharmaceutical dispensing, hospital admission and death records. We identified 97,875 women who smoked during pregnancy; of those, 233, 330 and 1057 were exposed to bupropion, NRT and varenicline in pregnancy, respectively. Propensity scores were used to match exposed women to those who were unexposed to any smoking therapy (1:10 ratio). Propensity scores and gestational age at exposure were used to match varenicline-exposed to NRT-exposed women (1:1 ratio). Time-dependent Cox proportional hazards models estimated hazard ratios (HR) with 95% confidence intervals (95% CI) for any adverse perinatal event (a composite of 10 unfavourable maternal and neonatal outcomes) and any major congenital anomaly. Results: The risk of any adverse perinatal event was not significantly different between bupropion-exposed and unexposed women (39.2% versus 39.3%, HR 0.93, 95% CI 0.73–1.19) and between NRT-exposed and unexposed women (44.8% vs 46.3%, HR 1.02, 95% CI 0.84–1.23), but it was significantly lower in women exposed to varenicline (36.9% vs 40.1%, HR 0.86, 95% CI 0.77–0.97). Varenicline-exposed infants were less likely than unexposed infants to be born premature (6.5% vs 8.9%, HR 0.72, 95% CI 0.56–0.92), be small for gestational age (11.4% vs 15.4%, HR 0.68, 95% CI 0.56–0.83) and have severe neonatal complications (6.6% vs 8.2%, HR 0.74, 95% CI 0.57–0.96). Among infants exposed to varenicline in the first trimester, 2.9% had a major congenital anomaly (3.5% in unexposed infants, HR 0.91, 95% CI 0.72–1.15). Varenicline-exposed women were less likely than NRT-exposed women to have an adverse perinatal event (38.7% vs 51.4%, HR 0.58, 95% CI 0.33–1.05). Conclusions: Pregnancy exposure to smoking cessation pharmacotherapies does not appear to be associated with an increased risk of adverse birth outcomes. Lower risk of adverse birth outcomes in varenicline-exposed pregnancies is inconsistent with recommendations that NRT be used in preference to varenicline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence from five large cohort studies did not find differences in stillbirth, birth outcomes, or any congenital anomaly for infants born to mothers with exposure to NRT, bupropion, or varenicline versus those who were unexposed to medications but whose mothers smoked.”
From Interventions for Tobacco Cessation in Adults, Including Pregnant Persons (2021) · cites this paper as [108]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“while the second showed no significant difference (HR = 1.00, 95% CI = 0.71-1.42)[41].”
From Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. (2021) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and the other showing no significant change in risk (HR = 0.77, 95% CI = 0.56-1.07)[41].”
From Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. (2021) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“there was no significant change in overall risk of any adverse perinatal event when comparing women who smoked who were exposed to NRT and those who were not (HR = 1.02, 95% CI = 0.84-1.23).”
From Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. (2021) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
THE ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS
(1974) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1974.tb93279.x · Cited by 1,341
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243 · cited 1×
“Pharmacotherapies for smoking cessation including varenicline, bupropion and nicotine replacement therapy (NRT) are more effective than behavioural cessation interventions in non-pregnant adults [6, 7]; however, little is known about their safety and efficacy in pregnancy [1, 8–10].”
Birth Spacing and Risk of Adverse Perinatal Outcomes: A Meta-analysis
Conde-Agudelo, A., Rosas-Bermúdez, A., & Kafury-Goeta, A. C. (2006) · JAMA · doi:10.1001/jama.295.15.1809 · Cited by 1,103
Karch, D. L., Dahlberg, L. L., & Patel, N. (2010) · PsycEXTRA Dataset · doi:10.1037/e587232010-001 · Cited by 745
Birth Spacing and Risk of Adverse Perinatal Outcomes: A Meta-Analysis
&NA; (2007) · Survey of Anesthesiology · doi:10.1097/01.sa.0000267038.80927.32 · Cited by 670
Nguyen, T.-L., Collins, G. S., Spence, J., Daurès, J.-P., Devereaux, P. J., Landais, P., & Le Manach, Y. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0338-0 · Cited by 512
Developmental Consequences of Fetal Exposure to Drugs: What We Know and What We Still Must Learn
Ross, E. J., Graham, D. L., Money, K. M., & Stanwood, G. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.147 · Cited by 476
Accelerated Metabolism of Nicotine and Cotinine in Pregnant Smokers
Dempsey, D., Jacob, P., & Benowitz, N. L. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.594 · Cited by 452
Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978-2005: (403792008-002)
(2008) · PsycEXTRA Dataset · doi:10.1037/e403792008-002 · Cited by 409
Research works printed but not linked: 10
- World Health Organization. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. Geneva: World Health Organization; 2013.
- National Centre for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular list of diseases and Alphabetic index of diseases. Sydney: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2008.
- New South Wales Department of Health. Maternity - Towards Normal Birth in NSW. Maternity and Child Health Unit - Strategic Development Division 2010.
- Hutchinson M. Western Australia’s mothers and babies, 2012: 30th annual report of the Western Australian midwives notification system; 2015.
- WHO Collaborating Centre for Drug Statistics Methodology. ATC alterations from 2005-2019. Geneva: World Health Organization; 2019. https://www.whocc.no/atc_ddd_alterations__cumulative/atc_alterations/?order_by=1. Accessed 7 July 2019
- Parsons LS. Performing a 1:N case-control match on propensity sore. Proceedings of the Twenty -Sixth Annual SAS Users Group International Conference; 2004.
- European Surveillance of Congenital Anomalies. EUROCAT prevalence data tables. Cases and prevalence (per 10,000 births) of all congenital anomaly subgroups for all registries, from 2012–2016 2018. http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed 9 Apr 2019.
- Pfizer Laboratories. Chantix (full prescribing information) 2019. http://labeling.pfizer.com/ShowLabeling.aspx?id=557. Accessed 2 Apr 2019.
- Taylor L, Pym M, Bajuk B, Sutton L, Travis S, Banks C. Validation study NSW midwives data collection 1998. Sydney: NSW Health Department; 2000.
- Greenhalgh EM, Scollo MM, Pearce M. 9.1 socio-economic position and disparities in tobacco exposure and use. In: Scollo MM, Winstanley MH, editors. Tobacco in Australia: facts and issues. Melbourne: Cancer Council Victoria; 2018.
Cited by
Interventions for Tobacco Cessation in Adults, Including Pregnant Persons
Patnode, C. D., Henderson, J. T., Coppola, E. L., Melnikow, J., Durbin, S., & Thomas, R. G. (2021) · JAMA · doi:10.1001/jama.2020.23541 · Cited by 212
Havard, A., Chandran, J. J., & Oei, J. L. (2022) · Addiction · doi:10.1111/add.15792 · Cited by 65
Self-citationFetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis.
Taylor, L., Claire, R., Campbell, K., Coleman‐Haynes, T., Leonardi‐Bee, J., Chamberlain, C., Berlin, I., Davey, M., Cooper, S., & Coleman, T. (2021) · Addiction · doi:10.1111/add.15185 · Cited by 53
“Preterm birth (at < 37 weeks) was an outcome in six studies, but only two were pooled [36,37]; three were without appropriate comparison groups [40,41,54] and one [39] duplicated findings from another included study [37].”
InfluentialMa, Q., Wang, H., Rolls, E. T., Xiang, S., Li, J., Li, Y., Zhou, Q., Cheng, W., & Li, F. R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02627-3 · Cited by 36
“The length of gestation was estimated by ultrasonography examination, last menstrual period, or clinical examination, which has been frequently used to estimate gestational age in previous studies [50, 51].”
MethodMaternal nicotine exposure induces congenital heart defects in the offspring of mice
Greco, E. R., Engineer, A., Saiyin, T., Lu, X., Zhang, M., Jones, D. L., & Feng, Q. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17328 · Cited by 21
“13 14– 17 It remains unclear whether these replacements are safe for the foetuses.”
Background
Metadata
- Authors
- Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A.
- Affiliations
- UNSW Sydney (AU)
- The University of Western Australia (AU)
- The University of Sydney (AU)
- Corresponding author
- Tran, Duong Thuy
- ORCID
- Venue
- BMC Medicine
- Published
- 2020-02-05
- Volume
- 18
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC7001233
- OpenAlex
- W3010465641
- Semantic Scholar
- 71347f9d2789d2e24dd3c097cb168402cbe775f1
- Cited by
- 29
- References
- 47
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Opin vísindi (Opin vísindi) (submittedVersion, cc-by)
- Funders
- Australian National Health and Medical Research Council (1028543)
- National Heart Foundation of Australia (100411)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- smoking cessation pharmacotherapy, pregnancy, varenicline, bupropion, nicotine replacement therapy, perinatal complications, major congenital malformations, preterm birth, small for gestational age, maternal smoking, drug safety in pregnancy, Australia, New South Wales, Western Australia, neonatal mortality, neonatal intensive care admission
- MeSH terms
- Adult, Female, Humans, Pregnancy, Risk Factors, Cohort Studies, Smoking Cessation, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. https://app.cochat.ai/papers/10.1186/s12916-019-1472-9
- The paper
- Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A. (2020). Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Medicine. https://doi.org/10.1186/s12916-019-1472-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.